- Home
- DCOM vs VRDN Comparison
DCOM vs VRDN Comparison
Compare DCOM & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DCOM | VRDN |
|---|---|---|
| Founded | 1864 | 2006 |
| Country | United States | United States |
| Employees | 902 | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | DCOM | VRDN |
|---|---|---|
| Price | $36.22 | $13.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 14 |
| Target Price | ★ $37.80 | $35.46 |
| AVG Volume (30 Days) | 262.3K | ★ 2.7M |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.81% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,706,000.00 |
| Revenue This Year | $21.40 | $13.73 |
| Revenue Next Year | $12.65 | $279.00 |
| P/E Ratio | $14.81 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $24.64 | $11.76 |
| 52 Week High | $37.75 | $34.29 |
Technical Indicators
Market Signals| Indicator | DCOM | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 55.20 | 24.57 |
| Support Level | $34.58 | $13.33 |
| Resistance Level | $37.07 | $18.95 |
| Average True Range (ATR) | 1.27 | 0.57 |
| MACD | -0.15 | 0.37 |
| Stochastic Oscillator | 49.21 | 10.66 |
Price Performance
Historical ComparisonAbout DCOM Dime Community Bancshares Inc.
Dime Community Bancshares Inc operates as a holding company. The company gathers deposits from customers within its market area and via the internet and invests them in multifamily residential, commercial real estate, commercial and industrial (C&I) loans, and one-to-four family residential real estate loans, and mortgage-backed securities, obligations of the U.S. government and government- sponsored enterprises (GSEs), and corporate debt and equity securities. The company has one reportable segment which is Community Banking.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.